SC questions bar on trans persons as blood donors
The Supreme Court on Wednesday urged the Centre to consult experts for a revision of the country's blood donation guidelines as it questioned the rationale behind excluding transgender persons branding the community 'high risk'.
The bench of justices Surya Kant and N Kotiswar Singh was hearing a batch of petitions challenging the guidelines issued by National Blood Transfusion Council (NBTC) in 2017 which prevented 'transgenders, men having sex with men (MSM) and female sex workers' from donating blood for being at 'high risk' for HIV, Hepatitis B or C infections.
'What is worrying me is are we going to brand all transgender persons as risk, thus, indirectly stigmatising the transgender community...this is something only experts can advise,' the court observed.
The Centre, represented by additional solicitor general (ASG) Aishwarya Bhati, said that the guidelines were not intended to stigmatise anyone but have been prepared with 'scientific temper' by NBTC which comprises doctors and experts in the field.
The court responded saying, 'What worries us is the element of discrimination. They have been isolated and excluded. Just think of something that such feeling does not come and health standards are not compromised.'
The court pointed out that with changing times, new technologies have emerged and there could be a way out to ensure any possibility of infections is checked and contained. 'The question we need to ask is, are we creating a segregated group. Already transgenders suffer from severe biases and prejudices. Does this (guidelines) not further it,' it observed.
While ASG Bhati said that she will go back to the experts on the court's suggestion, she argued that the guidelines must be viewed in light of the country's public health requirements and the available testing mechanisms across the nation.
'These guidelines must be seen from the perspective of public health as the idea is not to stigmatise anyone,' she said.
In response, justice Kant noted that the court was consciously refraining from expressing any personal views on the matter and does not intend to override the expertise of medical professionals.
The court, however, also recognised that transgender individuals already face significant bias and prejudice in society.
'Are we creating a kind of segregated group?...transgenders already suffer biases and prejudices,' justice Singh noted.
The judges observed that a solution must be found that ensures that the transgender community is not unfairly stigmatised, while also maintaining the necessary safety measures for blood donations.
'You please talk to them that what can be way out that as a community they are not stigmatised, and at the same time safety measures remain in force,' it orally observed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
This drug offers 99.9% protection against HIV, but there's a catch
The US FDA has approved lenacapavir, the first twice-yearly injection for HIV prevention, which provides near-complete protection. However, its cost — ₹24 lakh per shot — may make it inaccessible in India
New Indian Express
8 hours ago
- New Indian Express
Yoga mandirs to be set up in all district, taluk hospitals in Karnataka
BENGALURU: To expand the reach of yoga and integrate it into mainstream health care, the State Government will soon set up 'yoga mandirs' in all district and taluk hospitals, as well as community health centres, Health Minister Dinesh Gundu Rao announced on Saturday during the 11th International Day of Yoga celebrations held in Vidhana Soudha. Rao also mentioned that Mysuru is being proposed as the country's first 'yoga district', with the goal of ensuring that at least one person in every household regularly practices yoga. 'A proposal to declare Mysuru a yoga district has already been submitted to the Centre. Ashtanga Yoga, which has deep roots in the state, will be given special emphasis,' he said. This year's state-wide Yoga Day celebrations, led by the Ayush department, saw more than five lakh people participate in mass demonstrations held at over 10,000 locations. Governor Thaawar Chand Gehlot inaugurated the celebrations at Vidhana Soudha, where over 5,000 people performed yoga alongside other government officials. Various programmes such as 'yoga park', 'yoga dhanush', 'green yoga', 'yoga mahakumbha', and 'yoga sanyoga' were held to mark the day. Under the Yoga Dhanush programme, five lakh people were trained in yoga protocols, and steps are being taken to implement these in 5,000 schools across Karnataka.
Time of India
12 hours ago
- Time of India
Drug offers 99.9% HIV shield, but Indians will have to wait
Mumbai: A new drug promising 99.9% protection against HIV received approval from the US Food & Drug Administration (FDA) a few days ago, but the city's HIV rights activists are sceptical about its practical impact in India. The main concern stems from the new injectable drug lenacapavir's substantial cost of Rs 24 lakh ($28,218) per person for two injections taken six months apart. Also, NACO (National AIDS Control Organisation) has not fully embraced PrEP (pre-exposure prophylaxis) medications, the category to which lenacapavir belongs. "Our govt distributes condoms to break HIV transmission, it provides antiretroviral therapy drugs to prevent parent-to-child transmission of HIV, but it hasn't ever given PrEP to youngsters who are likely to indulge in high-risk behaviour," said health activist Ganesh Acharya. A couple of years ago, NACO made it mandatory for its counselling centres to disburse information on PrEP. He is alarmed because 75% of the 88% diagnosed with HIV in Mumbai between 2023-24 were in the 15-49 age group that is classified as young. PrEP is available for those seeking treatment in the private sector. PrEP, as a method to prevent HIV transmission before a risky exposure, has been around for almost 12 years. It was widely accepted in developed countries, but India's public health machinery never mentioned it until a few years ago. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 5 Books Warren Buffett Wants You to Read In 2025 Blinkist: Warren Buffett's Reading List Undo "They set up a committee, then a white paper was brought out that served as a backgrounder for guidelines that were drawn up last year. However, there has been no development since," said a doctor with a public hospital. Dr Ishwar Gilada of the People's Health Organisation (India) said PrEP is the lesser evil compared to HIV transmission. "The govt should distribute PrEP to check the spread of the disease, which has only been increasing in recent years. The total number of HIV-positive people in India increased from 2.2 million to 2.5 million in a few years," he added. The problem is more pronounced in Mumbai, he said, where the number of people with sexually transmitted diseases has been rising. "A recent survey in Mumbai among men who have sex with men found that 60% of them were positive for the human papilloma virus. While gonorrhoea and chlamydia vanished 25 years ago, their numbers are shooting up," said Dr Gilada. PrEP would be the solution, according to him. The govt could adopt a three-tier payment system for PrEP: Charge full cost from those who can afford it, subsidy for some, and free for those who cannot afford medications. Despite efforts, NACO officials were not available for comment. PrEP is not the only HIV-related policy that the govt hasn't acted on. Self-testing HIV kits, for instance, are not allowed in India. "We have self-testing kits for pregnancy, diabetes, and Covid, but policymakers fear about the mental health of people after a positive result in self-testing HIV kits," said Dr Gilada. The same logic is possibly behind the delay with introducing PrEP in the public health system, said a senior doctor, as a section of public health officials fear that giving PrEP would seem like a licence for risky behaviour. However, there is hope that lenacapavir would be available in India sooner rather than later. Bala of Bombay Gay said lenacapavir is a "monumental milestone forward in HIV treatment and prevention," but its pricing makes it inaccessible to Indian patients. "So, we have to wait and see if prices will come down over time," he added. Dr Gilada is positive Indian generic pharma companies licensed by Gilead Sciences can bring lenacapavir injections at below $100 per annum cost and may be rolled out soon. "India can do it," he said. In a statement released a couple of days ago, UNAIDS urged Gilead Lifesciences to drop the price of the new HIV prevention shot.
